Research programme: HIV integrase inhibitors - Amgen

Drug Profile

Research programme: HIV integrase inhibitors - Amgen

Alternative Names: HIV integrase inhibitors research programme - Amgen

Latest Information Update: 09 Dec 2003

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Tularik
  • Class
  • Mechanism of Action HIV integrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 09 Dec 2003 Discontinued - Preclinical for HIV infections treatment in USA (unspecified route)
  • 12 Jul 2001 Preclinical development for HIV infections treatment in USA (Unknown route)
  • 21 Oct 1999 Proteus International has merged with Therapeutic Antibodies to form Protherics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top